On Friday evening Ipsen announced the publication of positive results from a Phase III study evaluating Onivyde, an anti-cancer drug for which the laboratory shares rights with the Servier group.

The data, presented at the 2025 American Society of Clinical Oncology (ASCO) meeting, showed a median overall survival of 19.5 months in long-term survivors with metastatic pancreatic adenocarcinoma (mPDAC), a form of pancreatic cancer.

The trial focused on the first-line administration of Onivyde injection in combination with oxaliplatin, fluorouracil, and leucovorin in patients diagnosed at a younger age and with certain tumor and metastatic locations associated with long-term survival.

In a press release, Ipsen cited positive data, noting that patients with pancreatic adenocarcinoma live on average only four to six months after diagnosis.

For the record, Ipsen has exclusive marketing rights for the current and future indications of Onivyde in the United States, while Servier is responsible for distributing the product outside the United States, Taiwan, and Canada.

Ipsen also announced on Monday that it had launched a share buyback program for up to 600,000 shares, representing approximately 0.7% of its share capital.

The repurchased shares will mainly be used to cover the free share allocation plan for employees.

On the Paris Stock Exchange, Ipsen shares were down 0.6% on Monday morning in a Paris market that was down about 0.8%.


Copyright (c) 2025 CercleFinance.com. All rights reserved.